Empirical Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Empirical Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Buy	39,579 +8,011	+25%	+$68.9K	﹤0.01%	852
2026 Q1	$253K	Buy	31,568 +9,954	+46%	+$95.4K	﹤0.01%	860
2025 Q4	$252K	Buy	+21,614	New	+$210K	﹤0.01%	763

Other funds holding SPRY

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Empirical Wealth Management's SPRY Position: Q2 2026 in Review

Empirical Wealth Management increased its ARS Pharmaceuticals (SPRY) stake by 25% in Q2 2026, buying an estimated $68.9K and bringing the position to 39,579 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Empirical Wealth Management first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Empirical Wealth Management held 39,579 shares of ARS Pharmaceuticals worth $317K as of Q2 2026.
Empirical Wealth Management bought 8,011 ARS Pharmaceuticals shares in Q2 2026, an estimated $68.9K.
ARS Pharmaceuticals made up ﹤0.01% of Empirical Wealth Management's portfolio in Q2 2026, its #852 holding.
Empirical Wealth Management first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
30 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.